Results 31 to 40 of about 18,985 (204)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer

Journal of Bone Oncology, 2015
Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia.
Xinmin Zhao, Xichun Hu
doaj   +1 more source

Orthodontic tooth movement and root resorption in ovariectomized rats treated by systemic administration of zoledronic acid [PDF]

, 2012
Introduction: The effect of zoledronic acid, a potent and novel bisphosphonate, on tooth movement and orthodontically induced root resorption in osteoporotic animals systemically treated with zoledronic acid as similarly used in postmenopausal patients ...
Luppanapornlarp, Suwannee, Darendeliler, M. Ali, Yoshida, Noriaki, Gonzales, Carmen, Hotokezaka, Hitoshi, Hashimoto, Megumi, Sirisoontorn, Irin   +6 more
core   +1 more source

Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay

BMC Cancer, 2009
Previous data suggest that lipophilic statins such as fluvastatin and N-bisphosphonates such as zoledronic acid, both inhibitors of the mevalonate metabolic pathway, have anti-cancer effects in vitro and in patients.
Dexel Susanne, Reichelt Ralf, Fernando Augusta, Glaysher Sharon, Kurbacher Christian M, Knight Louise A, Reinhold Uwe, Cree Ian A   +7 more
doaj   +1 more source

Assessment of the Impact of Zoledronic Acid on Ovariectomized Osteoporosis Model Using Micro-CT Scanning. [PDF]

PLoS ONE, 2015
Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic acid on the cancellous bone microstructure and its effect on the level of β-catenin in a mouse model of postmenopausal osteoporosis.96 8-week-old specific ...
Bo Shuai, Lin Shen, Yanping Yang, Chen Ma, Rui Zhu, Xiaojuan Xu   +5 more
doaj   +1 more source

Osteonecrosis of the jaws associated with the use of yearly zoledronic acid: Report of 2 cases

, 2014
Background Once-yearly zoledronic acid has been proven effective in the management of osteoporosis. Osteonecrosis of the jaws (ONJ) related to its use has not been reported since its approval in 2007.
江俊斌;李正喆;郭生興;王逸平;鄭景暉;鄭世榮, Lee, Jang-Jaer;Cheng, Shih-Jung;Wang, Yi-Ping;Jeng, Jiiang-Huei;Chiang, Chun-Pin;Kok, Sang-Heng   +1 more
core   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

Zoledronic acid in breast cancer: latest findings and interpretations

Therapeutic Advances in Medical Oncology, 2011
The intravenous nitrogen-containing bisphosphonate zoledronic acid has been shown to block multiple steps in tumor metastasis (e.g. angiogenesis, invasion, adhesion, proliferation) in preclinical and translational studies.
Michael Gnant
doaj   +1 more source

Nitrogen‐Based Bisphosphonate Use and Risk of Cancer in Women Aged 50 Years and Older: A National Data Linkage Study

International Journal of Cancer, EarlyView.
Bisphosphonates are widely used to treat osteoporosis and to manage bone metastases in patients with breast cancer. Nitrogen‐based bisphosphonates may also broadly reduce cancer risk, but evidence remains inconsistent. This large population‐based data linkage study in women aged > 50 years found that, compared to no use of osteoporosis medicines ...
Karen M. Tuesley, Fiona Caristo, Katrina Spilsbury, Sallie‐Anne Pearson, Peter Donovan, Michael D. Coory, Christopher B. Steer, Susan J. Jordan   +7 more
wiley   +1 more source

Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass

, 2010
Ronald C Hamdy1,21Chair, Quillen Chair of Geriatrics and Gerontology, Quillen College of Medicine, East Tennessee State University, 2Staff Physician, Mountain Home Veterans’ Administration, Tennessee, USA Abstract: The availability of a once-a ...
Ronald C Hamdy, Hamdy, Ronald C., Ronald Hamdy   +2 more
core   +1 more source

Fracture risk and zoledronic acid therapy in men with osteoporosis [PDF]

, 2012
peer reviewedBACKGROUND: Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. METHODS: In
Papanastasiou, Philemon, Su, Guaqin, Witvrouw, Richard, Russo, L., Lipschitz, Stanley, Dimai, H. P., Brixen, K., Kaufman, J.M., Lipschitz, S., Vanderschueren, Dirk, Antunez, O., Rizzoli, Rene, Su, G., Boonen, Steven, Langdahl, Bente, Zanchetta, Jose, Hruska, Josef, Orwoll, Eric, Orwoll, E., Bucci-Rechtweg, C., Vanderschueren, D., Kaufman, Jean, REGINSTER, Jean-Yves, Incera, Elodie, Kaufman, J.-M., Eriksen, E., Lippuner, K., Witvrouw, R., Boonen, S., Langdahl, B., Kaufman, Jean-Marc, Rizzoli, R., Reginster, J.Y., Lippuner, Kurt, Hruska, J., Dimai, Hans Peter, Russo, Luis, Su, Guoqin, Eriksen, Erik, Antunez, Oscar, Langdahl, Bente Lomholt, Incera, E., Claessens, Frank, Papanastasiou, P., Claessens, F., Dimai, H.P., Bucci-Rechtweg, Christina, Brixen, Kim, Zanchetta, J.   +48 more
core   +1 more source